AbbVie Inc. (BMV:ABBV)

Market Cap	6.07T
Revenue (ttm)	1.17T
Net Income (ttm)	84.92B
Shares Out	n/a
EPS (ttm)	47.83
PE Ratio	71.43
Forward PE	13.92
Dividend	123.97 (3.39%)
Ex-Dividend Date	Apr 15, 2025

Volume	236
Average Volume	516
Open	3,656.67
Previous Close	3,661.21
Day's Range	3,465.50 - 3,656.67
52-Week Range	2,625.04 - 4,529.31
Beta	0.54
RSI	37.47
Earnings Date	Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD